Molecular Partners Ag (MOLN) Cash from Operations (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Cash from Operations of 18188.38 for Q1 2026, up 4.26% year-on-year from 17445.58 in Q1 2025, and up 99.97% on a QoQ basis from 64081030.6 in Q4 2025.
Molecular Partners Ag (MOLN) Cash from Operations (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Cash from Operations for 7 consecutive years, with 18188.38 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Operations rose 4.26% year-over-year to 18188.38 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 62854547.06 (up 4.83% YoY) and the FY2025 annual result came in at 64131210.02, up 5.18% from the prior year.
- Cash from Operations advanced to 18188.38 in Q1 2026 per MOLN's latest filing, from 64081030.6 in the prior quarter.
- Over the last five years, Cash from Operations for MOLN reached as high as 156597882.47 in Q2 2022 and fell as low as 156201913.72 in Q3 2022.
- A 5-year average of 4196191.7 and a median of 18997.24 in 2025 frame the typical range for Cash from Operations.
- The largest YoY upside for Cash from Operations was 635.85% in 2022 against a maximum downside of 373.36% in 2022.
- Year by year, Cash from Operations stood at 122936223.52 in 2022, then plunged by 154.07% to 66471055.32 in 2023, then dropped by 1.67% to 67580315.95 in 2024, then climbed by 5.18% to 64081030.6 in 2025, then soared by 99.97% to 18188.38 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 18188.38, 64081030.6, and 37678168.26 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -18,188.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,188.38 |
| Mar 31, 2026 | -18,188.38 |
| Dec 31, 2025 | -64.08 Mn |
| Dec 31, 2025 | -64.08 Mn |
| Sep 30, 2025 | 37.68 Mn |
| Sep 30, 2025 | 37.68 Mn |
| Jun 30, 2025 | -36.43 Mn |
| Jun 30, 2025 | -36.43 Mn |
| Mar 31, 2025 | -18,997.24 |
| Mar 31, 2025 | -18,997.24 |
| Dec 31, 2024 | -67.58 Mn |
| Dec 31, 2024 | -67.58 Mn |
| Sep 30, 2024 | 37.77 Mn |
| Sep 30, 2024 | 37.77 Mn |
| Jun 30, 2024 | -36.22 Mn |
| Jun 30, 2024 | -36.22 Mn |
| Mar 31, 2024 | -19,532.74 |
| Mar 31, 2024 | -19,532.74 |
| Dec 31, 2023 | -66.47 Mn |
| Dec 31, 2023 | -66.47 Mn |